Compare Dollar General Corp. (DG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Summit Therapeutics Inc — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Dollar General Corp. is far larger — about 2× Summit Therapeutics Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Summit Therapeutics Inc for 16 Days on average.
| DG | SMMT | |
|---|---|---|
Market Cap | $27.42B | $13.71B |
Volume | 2,291,517 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $26.38 |
52-Week Low | $95.94 | $12.43 |
Typical Hold Time | 59 Days | 16 Days |
Enterprise Value | $41.60B | $13.04B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 1.73% today, with a bullish technical signal and support near $123. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $2.48 beating estimates of $2.01. Revenue grew to $40.61 billion in 2025, though net margins compressed to 2.77%. Recent news highlights tariff refunds boosting margins and expansion of same-day delivery via Instacart.
The outlook is positive with a consensus price target of $137.27, implying ~10% upside. Strengths include a low P/S of 0.63 and ROE of 19.69%, but risks include margin pressure from inflation and competitive threats. Analyst sentiment is bullish with 55.77% buy ratings, though insider selling and macroeconomic headwinds warrant caution.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
